CBE
Cannabielsoin · CBE · Discovered 1973
Discover CBE (Cannabielsoin), a rare cannabinoid metabolite of CBD. Learn about its formation from CBD metabolism, what limited research reveals about its properties, and its place in cannabinoid science.
Psychoactive
No
Discovered
1973
Effects
3 documented
Benefits
1 studied
Overview
Cannabielsoin (CBE) is a rare cannabinoid that forms as a metabolite of CBD in both the cannabis plant and within the human body after CBD consumption. It was first identified in 1973 and is produced when CBD undergoes photochemical or enzymatic oxidation. In the cannabis plant, CBE can form when CBD is exposed to light and air, similar to how CBN forms from THC degradation. In human metabolism, CBD is partially converted to CBE through hepatic (liver) processing.
CBE is one of the most obscure cannabinoids in scientific literature. Very few studies have specifically examined its pharmacological properties, and those that exist are decades old with limited scope. The compound's status as a metabolite of CBD makes it scientifically interesting from a pharmacokinetic perspective — understanding how much CBD is converted to CBE in the body, and whether CBE has its own biological activity, is relevant to understanding CBD's overall therapeutic profile.
Despite its obscurity, CBE's existence highlights the remarkable complexity of cannabinoid chemistry. The cannabis plant produces over 100 identified cannabinoids, and many more form through post-harvest processing, storage, and human metabolism. Each of these compounds potentially has unique biological activity, but the vast majority remain pharmacologically uncharacterized. CBE stands as a reminder that our understanding of cannabis chemistry is still in its early stages.
Mechanism of Action
CBE's mechanism of action is not characterized in published research. As a CBD metabolite with structural similarities to its parent compound, CBE may retain some affinity for the same molecular targets as CBD, including serotonin receptors, TRP channels, and PPARs, but this is speculative. No binding studies or functional assays specifically examining CBE's receptor interactions have been published. Its non-psychoactive nature suggests minimal CB1 receptor activity.
Therapeutic Effects
Potential Benefits
Understanding CBD Metabolism
Scientific context. CBE's primary research relevance is as a metabolite of CBD. Understanding the proportion of CBD converted to CBE in the body may be important for optimizing CBD dosing and understanding its pharmacokinetic profile. Whether CBE itself contributes to CBD's therapeutic effects is unknown.
Side Effects & Risks
- ⚠No documented side effects due to absence of research
- ⚠Safety profile unknown
- ⚠Formed naturally as a metabolite of CBD in the body
Concentration & Sources
Typical Concentration
Trace amounts in aged or light-exposed cannabis; formed as a metabolite of CBD in human metabolism; not commercially available
Found In
Formed as a photochemical product of CBD in aged cannabis. Produced as a metabolite in the human body after CBD consumption. Not available as an isolated commercial product.
Legal Status
Not specifically regulated. Legal in most jurisdictions as a naturally occurring, non-psychoactive minor cannabinoid and CBD metabolite.
Research Summary
CBE is among the least studied cannabinoids. Identified in 1973, it has been the subject of very few published studies. Its primary scientific significance lies in its role as a CBD metabolite, which has implications for understanding CBD pharmacokinetics and metabolism. No systematic pharmacological characterization has been performed, and no therapeutic applications have been identified or investigated. The compound serves as an example of the vast uncharted territory in cannabinoid science, where dozens of naturally occurring compounds await basic research to determine whether they possess useful biological activity.
Related Cannabinoids
CBE FAQ
What is CBE?
CBE (cannabielsoin) is a rare cannabinoid that forms as a metabolite or degradation product of CBD. It can be produced in the cannabis plant when CBD is exposed to light and air, or in the human body when CBD is metabolized by the liver. CBE is non-psychoactive and is one of the least studied cannabinoids in scientific literature.
Does CBE have any therapeutic benefits?
No therapeutic benefits have been identified for CBE. The compound has not been the subject of preclinical or clinical research investigating specific therapeutic applications. Its properties are essentially unknown beyond its non-psychoactive nature and its origin as a CBD metabolite.
Is CBE found in CBD products?
CBE may be present in trace amounts in CBD products, particularly those that have been exposed to light or stored for extended periods, as light can convert some CBD to CBE. It may also form in the body after CBD consumption as a metabolite. However, the amounts would be very small and unlikely to have any noticeable effect.
Is CBE safe?
There is no published safety data specifically for CBE. However, since it naturally forms as a metabolite when the body processes CBD, it is likely that humans are regularly exposed to small amounts of CBE when consuming CBD products. No adverse effects have been attributed to CBE in the scientific literature.
Continue Exploring
Disclaimer: Cannabinoid information is provided for educational purposes only. Medical benefits are based on published research and are not intended as medical advice. Individual responses to cannabinoids vary. Always consult a healthcare professional before using cannabis for medical purposes. Legal status information is current as of publication but may change — verify your local laws.